Overview

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to explore the maintained efficacy, tolerability, and safety of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with other oral atypical antipsychotic medication.

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Taiwan Ltd

Treatments:

Paliperidone Palmitate